Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024
Comparison of PSMA immunohistochemistry scoring systems to parametric [<sup>18</sup>F]PSMA-1007 PET/MRI in primary prostate cancerNiloefar Ahmadi Bidakhvidi, Thomas Gevaert, Maxim De Schepper, et al.
EJNMMI Research|April 30, 2021
Parameters predicting [<sup>18</sup>F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancerNiloefar Ahmadi Bidakhvidi, Annouschka Laenen, Sander Jentjens, et al.
The Journal of Urology|November 14, 2019
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node DissectionCédric Draulans, Wouter Everaerts, Sofie Isebaert, et al.
BMC Cancer|April 3, 2018
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trialLorenzo Tosco, Annouschka Laenen, Thomas Gevaert, et al.
Neurourology and Urodynamics|July 5, 2022
The key role of levator ani thickness for early urinary continence recovery in patients undergoing robot-assisted radical prostatectomy: A multi-institutional studyManuela Tutolo, Giuseppe Rosiello, Giorgio Stabile, et al.
Clinical Nuclear Medicine|February 1, 2023
A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer: Preclinical Evaluation and Interim Results From a Multicenter Clinical TrialJose M Abascal Junquera, Nina N Harke, Jochen C Walz, et al.
World Journal of Urology|March 13, 2019
Metastasectomy for visceral and skeletal oligorecurrent prostate cancerAntonino Battaglia, Gaëtan Devos, Karel Decaestecker, et al.
World Journal of Urology|March 30, 2020
Correction to: Metastasectomy for visceral and skeletal oligorecurrent prostate cancerAntonino Battaglia, Gaëtan Devos, Karel Decaestecker, et al.
JMIR Research Protocols|December 15, 2018
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II TrialCédric Draulans, Steven Joniau, Valérie Fonteyne, et al.
European Urology|September 27, 2022
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate CancerGaëtan Devos, Lorenzo Tosco, Marcella Baldewijns, et al.
Pageof 11